Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Moximed said today that it pulled in a $33 million Series B round for its KineSpring knee implant, which is designed to reduce the load on the joint while sparing its anatomy.
The Hayward, Calif.-based company said new backer Vertex Venture Holdings joined prior investors New Enterprise Assoc., Gilde Healthcare Partners, Morgenthaler Ventures and GBS Venture Partners in the round. Read more
Medtronic said it’s launching a clinical trial to compare in-office implantation of its Reveal Linq cardiac monitor with hospital implantation.
The Reveal Linq device is designed to be implanted beneath the skin on the upper left side of the chest and is indicated for monitoring patients experiencing dizziness, palpitation, fainting or syncope, chest pain and cardiac arrhythmias. Billed as the world’s smallest cardiac monitor, it’s about 1/3 the size of a triple-A battery, Medtronic said, and is designed to work for 3 years using the company’s CareLink network. Read more
The FDA is withdrawing 47 draft guidance documents published before the end of 2013 that it never finalized or acted on.
Agency officials posted the announcement in the Federal Register, explaining that the move is designed to boost efficiency and transparency regarding its development of guidance documents. Read more